Triple threat: new combo tackles rare lung cancer
NCT ID NCT05765084
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial is testing whether adding an immunotherapy drug (atezolizumab) and a personalized vaccine (WT1/DC) to standard chemotherapy can safely improve outcomes for people with a rare type of mesothelioma. The study plans to enroll 15 adults with epithelioid malignant pleural mesothelioma that cannot be removed by surgery. The main goals are to check safety and see if the treatment shrinks tumors or slows the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab (PD-L1 inhibitor) and WT1/DC vaccine (dendritic cells loaded with WT1 protein)
What this could lead to
If successful, this could lead to a new first-line treatment option that improves tumor response and survival for people with epithelioid malignant pleural mesothelioma.
What could go wrong
This is a very early, small trial (15 people) focused on safety and feasibility. The combination may cause significant side effects or fail to show meaningful clinical benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT PLEURAL MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AZ Maria Middelares
RECRUITINGGhent, 9000, Belgium
Contact
-
Antwerp University Hospital
RECRUITINGEdegem, Antwerp, 2650, Belgium
Contact Email: •••••@•••••
-
VITAZ
RECRUITINGSint-Niklaas, 9100, Belgium
Contact